Blog Archive

From The Corner Office Q2 2024Ken VanLuvanee, President & CEO Apologies for the delay—this past quarter, we’ve championed a large number of Sponsor-FDA meetings and have had even more informal interactions in our quest to ...

FACET BY THE NUMBERS Total ESG submissions to FDA Apr – June 2024:  Over 30! Early-Stage Development Highlights 6 formal FDA meetings, 1 investigator-initiated IND, over 25 IND amendments (e.g., new protocols/amendments, CMC up...

Team Focus – New Facet Team Members We are excited to announce the addition of 3 new team members. Eva Raspor, Strategic Regulatory Writer Facet welcomes Eva Raspor to our team as a Strategic Regulatory Writer.  Eva has a...

Facet Donates to SNMMI’s Mars Shot Facet is proud to be a SNMMI Mars Shot Research Fund donor in 2024.  The goal of this fund is to improve and extend the lives of patients with cancer through innovation with radiopharmaceutica...

Facet Attends SNMMI In June, Dr. Lisa Jenkins VanLuvanee attended the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting.  SNMMI is an educational, scientific, research, and networking organization focus...

Facet Attends Psychedelic Therapeutics & Drug Development Conference In May, Dr. Jason Mercer attended the Psychedelic Therapeutics & Drug Development Conference.  This conference brought together academic and industry ...

Facet Attends the Market Access Society of America Symposium Dr. Randy Goodman attended the May 21st Market Access Society of America Symposium.  This global conference brings together government and industry experts, researche...

Facet Attends the Food and Drug Law Institute (FDLI) Annual Conference In May, Dr. Jason Mercer attended the Food and Drug Law Institute (FDLI) Annual Conference.  FDLI brings together legal and regulatory professionals that w...

Facet Joins PET CMC Coalition In May, Facet joined the Coalition of PET Drug Manufacturers, a not-for-profit organization that seeks to help PET drug manufacturers to gain and maintain US marketing authorizations for PET drugs ...

START Pilot Program Updates In our 4Q2023 newsletter, we reported on FDA’s Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.  This program is designed to help facilitate more efficient devel...